文献速递肝病

8周bemnifosbuvir联合ruzazvir方案治疗慢性丙型肝炎的疗效与安全性:II期研究结果

Efficacy and safety of an 8-week bemnifosbuvir and ruzasvir regimen in chronic hepatitis C: Results from a Phase 2 study.
PubMed 文献 · Hepatology · 2026-10-02

这项单臂II期研究评估了bemnifosbuvir 550 mg联合ruzazvir 180 mg每日一次、疗程8周,在初治慢性HCV感染(任意基因型,伴或不伴代偿性肝硬化)患者中的疗效与安全性。结果显示,ITT人群SVR12为90%(248/275;95%CI:86-93%),PK/PC-PP人群为98%(210/215;95%CI:95-99%),EE-PP人群为95%(245/259;95%CI:91-97%),且未报告药物相关严重不良事件或因药物相关不良事件导致的提前停药。

要点

  • 8周bemnifosbuvir联合ruzazvir方案在初治慢性HCV患者中SVR12达90%(ITT)至98%(PK/PC-PP)。
  • 基线NS5A RASs患者占27%,代偿性肝硬化患者占13%,方案仍显示高SVR12。
  • 安全性良好,无药物相关严重不良事件或因此提前停药。

核心结论

  • 8周bemnifosbuvir联合ruzazvir方案在初治慢性HCV患者中实现高SVR12率,且耐受性良好。

研究设计与样本

  • 单臂II期研究,纳入275例初治慢性HCV感染(任意基因型,伴或不伴代偿性肝硬化)患者,接受bemnifosbuvir 550 mg联合ruzazvir 180 mg每日一次治疗8周。

主要发现

  • ITT人群SVR12为90%(248/275;95%CI:86-93%)。
  • PK/PC-PP人群SVR12为98%(210/215;95%CI:95-99%)。
  • EE-PP人群SVR12为95%(245/259;95%CI:91-97%)。
  • PK/PC-PP人群中5例患者出现病毒学失败(治疗后复发)。
  • 未报告药物相关严重不良事件或因药物相关不良事件导致的提前停药。

临床怎么用

  • 该8周联合方案可能为初治慢性HCV患者(包括代偿性肝硬化及基线NS5A RASs者)提供短疗程治疗选择。

局限性

  • 研究为单臂设计,缺乏对照,结论需进一步随机对照试验验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: Bemnifosbuvir and ruzasvir are potent pan-genotypic inhibitors of the hepatitis C virus (HCV) NS5B polymerase and NS5A protein, respectively. This single-arm, Phase 2 study evaluated the efficacy and safety of bemnifosbuvir and ruzasvir in treatment-naïve patients with chronic HCV infection of any genotype, with or without compensated cirrhosis. APPROACH AND RESULTS: Patients received bemnifosbuvir 550 mg and ruzasvir 180 mg once daily for 8 weeks (intention-to-treat [ITT] population. The primary efficacy endpoint was the proportion of patients achieving a sustained virologic response at 12 weeks post-treatment (SVR12) in the Pharmacokinetic and Pill-Compliant Per-Protocol (PK/PC-PP) population. Secondary efficacy endpoints included SVR12 in the Efficacy Evaluable Per-Protocol (EE-PP; those with outcomes regardless of study drug adherence) and safety (all dosed) populations, virologic failure, and SVR24. Of the 275 patients enrolled and who received treatment with bemnifosbuvir and ruzasvir, 13% had compensated cirrhosis and 27% had NS5A resistance-associated substitutions (RASs) at baseline. SVR12 was 90% (248/275; 95% CI: 86-93%) in the ITT population, 98% (210/215; 95% CI: 95-99%) in the PK/PC-PP population, and 95% (245/259; 95% CI: 91-97%) in the EE-PP population. Five patients in the PK/PC-PP population experienced virologic failure (post-treatment relapse). No drug-related serious adverse events or premature treatment discontinuations due to drug-related adverse events were reported. CONCLUSIONS: An 8-week treatment with bemnifosbuvir and ruzasvir resulted in high rates of SVR12 across genotypes, regardless of the presence or absence of baseline RASs, and was well tolerated among treatment-naïve HCV patients.

来源:Hepatology,查看原文。版权归原作者所有。

引用

  1. Jucov A, Conway B, Feld JJ, et al. Efficacy and safety of an 8-week bemnifosbuvir and ruzasvir regimen in chronic hepatitis C: Results from a Phase 2 study. Hepatology. 2026. PMID: 42826065. doi:10.1097/HEP.0000000000001871

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。